bmiPV1frameBMI is working with a network of collaborators and partners to develop and commercialize their pipeline of innovative vaccines directed against specific human pathogens through the application of their epitope-protection and other key technologies.

orangecurved arrowDownload our recent publication in PLOS ONE describing the inactivation of polio using gamma irradiation: Click here.

ultra-IPV is an inactivated polio vaccine, based on Sabin strains, which introduces a number of key advantages over current polio vaccine options.  BMI’s novel non-chemical, UV-light mediated inactivation process will lead to a lower cost IPV and promises to maintain eradication, but with greater global safety and biosecurity compared with existing vaccines. 

orangecurved arrowFind out more about our technology

Download our White Paper

logo2019f2
 BMI is a innov
ative, privately-held vaccine design and development company located in Frederick, Maryland, USA.
Contact Us     Email: polio@bmi-md.com      Phone: (301) 378-2551  Info: Download White Paper
Download our recent publication in PLOS ONE describing the inactivation of polio using gamma irradiation: Click here.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok